InflaRx N.V. (NASDAQ:IFRX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of InflaRx N.V. (NASDAQ:IFRX) have been given an average recommendation of “Moderate Buy” by the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $7.3333.

IFRX has been the subject of a number of research analyst reports. Zacks Research lowered shares of InflaRx from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 25th. HC Wainwright boosted their target price on shares of InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Raymond James Financial upgraded InflaRx from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $7.00 to $9.00 in a report on Wednesday, May 13th. Cantor Fitzgerald lifted their target price on shares of InflaRx from $4.00 to $6.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Wall Street Zen upgraded InflaRx from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th.

Hedge Funds Weigh In On InflaRx

Large investors have recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC purchased a new stake in InflaRx in the 2nd quarter valued at $25,000. Cubist Systematic Strategies LLC increased its holdings in InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares during the last quarter. AXQ Capital LP purchased a new stake in shares of InflaRx in the 2nd quarter valued at $41,000. HRT Financial LP acquired a new stake in shares of InflaRx during the fourth quarter worth about $47,000. Finally, Concurrent Investment Advisors LLC boosted its position in InflaRx by 56.9% in the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after buying an additional 19,200 shares during the period. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Stock Performance

NASDAQ:IFRX opened at $2.23 on Monday. The stock has a 50-day simple moving average of $1.99 and a two-hundred day simple moving average of $1.66. InflaRx has a 52-week low of $0.80 and a 52-week high of $2.95. The firm has a market capitalization of $328.64 million, a PE ratio of -3.84 and a beta of 2.48.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04). Equities analysts forecast that InflaRx will post -0.31 earnings per share for the current fiscal year.

InflaRx Company Profile

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.